Jordan P Lerner-Ellis1, Saud H Aldubayan2, Amy Lovelette Hernandez3, Melissa Allard Kelly3, Aaron J Stuenkel4, Jennifer Walsh4, Victoria A Joshi5. 1. Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada; Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Laboratory for Molecular Medicine, Partners Healthcare Center for Personalized Genetic Medicine, Cambridge, MA, USA. 2. Department of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address: sdubayan@gmail.com. 3. Laboratory for Molecular Medicine, Partners Healthcare Center for Personalized Genetic Medicine, Cambridge, MA, USA. 4. Boston University, Boston, MA, USA. 5. Laboratory for Molecular Medicine, Partners Healthcare Center for Personalized Genetic Medicine, Cambridge, MA, USA; Departments of Pathology, Massachusetts General Hospital and Brigham and Women's Hospital, Boston, MA, USA.
Abstract
INTRODUCTION: In this study, patients suspected of having a clinical diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS) and Thoracic Aortic Aneurysms and Dissections (TAAD) were referred for genetic testing and examined for mutations in the FBN1, TGFβR1, TGFβR2 and ACTA2 genes. METHODS: We examined 594 samples from unrelated individuals and different combinations of genes were sequenced, including one or more of the following: FBN1, TGFβR1, TGFβR2, ACTA2, and, in some cases, FBN1 was analyzed by MLPA to detect large deletions. RESULTS: A total of 112 patients had a positive result. Of those, 61 had a clinical diagnosis of MFS, eight had LDS, three had TAAD and 40 patients had clinical features with no specific diagnosis provided. A total of 44 patients had an inconclusive result; of these, 12 patients were referred with a clinical diagnosis of MFS, 4 with LDS and 9 with TAAD and 19 had no clinical diagnosis. A total of 89 mutations were novel. CONCLUSION: This study reveals the rate of detection of variants in several genes associated with MFS, LDS and TAAD. The evaluation of patients by individuals with expertise in the field may decrease the likelihood of ordering unnecessary molecular testing. Nevertheless, genetic testing supports the diagnosis of MFS, LDS and TAAD.
INTRODUCTION: In this study, patients suspected of having a clinical diagnosis of Marfan Syndrome (MFS), Loeys-Dietz Syndrome (LDS) and Thoracic Aortic Aneurysms and Dissections (TAAD) were referred for genetic testing and examined for mutations in the FBN1, TGFβR1, TGFβR2 and ACTA2 genes. METHODS: We examined 594 samples from unrelated individuals and different combinations of genes were sequenced, including one or more of the following: FBN1, TGFβR1, TGFβR2, ACTA2, and, in some cases, FBN1 was analyzed by MLPA to detect large deletions. RESULTS: A total of 112 patients had a positive result. Of those, 61 had a clinical diagnosis of MFS, eight had LDS, three had TAAD and 40 patients had clinical features with no specific diagnosis provided. A total of 44 patients had an inconclusive result; of these, 12 patients were referred with a clinical diagnosis of MFS, 4 with LDS and 9 with TAAD and 19 had no clinical diagnosis. A total of 89 mutations were novel. CONCLUSION: This study reveals the rate of detection of variants in several genes associated with MFS, LDS and TAAD. The evaluation of patients by individuals with expertise in the field may decrease the likelihood of ordering unnecessary molecular testing. Nevertheless, genetic testing supports the diagnosis of MFS, LDS and TAAD.
Authors: Mine Arslan-Kirchner; Eloisa Arbustini; Catherine Boileau; Philippe Charron; Anne H Child; Gwenaelle Collod-Beroud; Julie De Backer; Anne De Paepe; Anna Dierking; Laurence Faivre; Sabine Hoffjan; Guillaume Jondeau; Britta Keyser; Bart Loeys; Karin Mayer; Peter N Robinson; Jörg Schmidtke Journal: Eur J Hum Genet Date: 2015-10-28 Impact factor: 4.246
Authors: Jeffrey A Schubert; Benjamin J Landis; Amy R Shikany; Robert B Hinton; Stephanie M Ware Journal: Am J Med Genet A Date: 2016-02-07 Impact factor: 2.802
Authors: Dianna M Milewicz; Alan C Braverman; Julie De Backer; Shaine A Morris; Catherine Boileau; Irene H Maumenee; Guillaume Jondeau; Arturo Evangelista; Reed E Pyeritz Journal: Nat Rev Dis Primers Date: 2021-09-02 Impact factor: 65.038
Authors: Yskert von Kodolitsch; Julie De Backer; Helke Schüler; Peter Bannas; Cyrus Behzadi; Alexander M Bernhardt; Mathias Hillebrand; Bettina Fuisting; Sara Sheikhzadeh; Meike Rybczynski; Tilo Kölbel; Klaus Püschel; Stefan Blankenberg; Peter N Robinson Journal: Appl Clin Genet Date: 2015-06-16
Authors: Alexander G Bick; Hiroko Wakimoto; Kimberli J Kamer; Yasemin Sancak; Olga Goldberger; Anna Axelsson; Daniel M DeLaughter; Joshua M Gorham; Vamsi K Mootha; J G Seidman; Christine E Seidman Journal: Proc Natl Acad Sci U S A Date: 2017-10-09 Impact factor: 11.205
Authors: Margot A Cousin; Michael T Zimmermann; Angela J Mathison; Patrick R Blackburn; Nicole J Boczek; Gavin R Oliver; Gwen A Lomberk; Raul A Urrutia; David R Deyle; Eric W Klee Journal: Cold Spring Harb Mol Case Stud Date: 2017-07-05